Physician profile
Michael Sheety
NPI 1871578120
$5,993.29
in general payments reported to CMS, 2019-2025
23 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,092 · 2020: $139 · 2021: $1,709 · 2022: $592 · 2023: $342 · 2024: $641 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,352 · Travel and Lodging: $88.09 · Entertainment: $21.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,351.83 |
| Travel and Lodging | $88.09 |
| Entertainment | $21.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $3,291.18 | 2019-2025 | |
| Alcon Vision LLC | $412.17 | 2019-2025 | Clareon, Tryptyr, Precision 1 |
| Kala Pharmaceuticals, INC. | $371.94 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $364.99 | 2019-2023 | Tecnis Iol, Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $327.44 | 2025 | |
| Allergan, INC. | $318.68 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $273.49 | 2023-2024 | Miebo, Xiidra |
| Harrow Eye, LLC | $150.66 | 2025 | Vevye |
| Rxsight INC | $136.28 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $90.76 | 2021-2023 | |
| Oyster Point Pharma, INC. | $51.54 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sight Sciences, INC. | $34.68 | 2021 | |
| Abbvie INC. | $28.72 | 2023 | Lumigan, Alphagan P |
| Optos, INC. | $21.98 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $19.59 | 2024 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sheety listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.